Clinical references

Micropressure therapy and the Meniett generator are based on many years of research both in the U.S. and Internationally. Short- and long-term results have been studied in Meniere’s disease patients, including randomized, double-blinded, placebo-controlled trials. Research concludes that Meniett therapy is a simple and effective treatment for the vertigo symptoms of Meniere’s disease.

Randomized Controlled Trials

  1. Gürkov R, Filipe Mingas LB, Rader T, Louza J, Olzowy B, Krause E. Effect of transtympanic low-pressure therapy in patients with unilateral Meniere’s disease unresponsive to betahistine: A randomised, placebo-controlled, double-blinded, clinical trial. J Laryngol Otol 2012;126:356-362.
  2. Thomsen J, Sass K, Odkvist L, Arlinger S. Local overpressure treatment reduces vestibular symptoms in patients with Meniere’s disease: A clinical, randomized, multicenter, double-blind, placebo-controlled study. Otology and Neurotology 2005;26:68-73.
  3. Gates GA, Green J, Tucci DL, Telian SA. The effects of transtympanic micropressure treatment in people with unilateral Meniere’s disease. Arch Otolaryngol Head Neck Surg 2004;130:718-725.
  4. Gates GA, Verrall A, Green JD Jr, et al. Meniett clinical trial: long-term follow-up. Arch Otolaryngol Head Neck Surg 2006;132:1311-1316.
  5. Russo FY, Nguyen Y, De Seta D, et al. Meniett device in meniere disease: Randomized, double-blind, placebo-controlled multicenter trial. Laryngoscope. 2017 Feb;127(2):470-475. Epub 2016 Aug 12.
  6. Covelli E, Volpini L, Atturo F, Benincasa AT, Filippi C, Tarentini S, Marrone V, Monini S, Vestri A, Barbara M. Delayed Effect of Active Pressure Treatment on Endolymphatic Hydrops. Audiol Neurootol. 2017;22(1):24-29. Epub 2017 May 18.
  7. Odkvist LM, Arlinger S, Billermark E, Densert B, Lindholm S, Wallqvist J. Effects of middle ear pressure changes on clinical symptoms in patients with Meniere’s disease – A clinical multicentre placebo-controlled study. Acta Oto-Laryngol Suppl 2000;99-101.

Other Clinical References

  1. Barbara M, Monini S, Chiappini I, Filipo R. Meniett therapy may avoid vestibular neurectomy in disabling Meniere’s disease. Acta Oto-Laryngol 2007;127:1136-1141.
  2. Barbara M, Lazzarino AI, Biagini M, Costa M, Monini S. Influence of Meniett treatment on hearing. Acta Oto-Laryngol 2010;130:1256-1259.
  3. Barbara M, Monini S, Chiappini I, Filipo R. Meniett therapy may avoid vestibular neurectomy in disabling Meniere’s disease. Acta Oto-Laryngol 2007;127:1136-1141.
  4. Basura GJ, Lin GC, Telian SA. Comparison of second-echelon treatments for Ménière’s disease. JAMA Otolaryngol Head Neck Surg. 2014;140(8):754-761.
  5. Buchanan MA, Rai A, Prinsley PR. Initial UK experience of patient satisfaction with the Meniett® device for Ménière’s disease treatment. J Laryngol Otol. 2010;124(10):1067-1072.
  6. Franz B, van der Laan F. P-100 in the treatment of Ménière’s disease: a clinical study. Int Tinnitus J. 2005;11(2):146-149.
  7. Gates GA, Green JD. Intermittent pressure therapy of intractable Ménière’s disease using the Meniett device: a preliminary report. Laryngoscope. 2002;112:1489-1493.
  8. Huang W, Liu F, Gao B, Zhou Z. Clinical long-term effects of Meniett pulse generator for Meniere’s disease. Acta Oto-Laryngologica. 2009;129(8):819-825.
  9. Rajan GP, Din S, Atlas MD. Long-term effects of the Meniett device in Ménière’s disease: the Western Australian experience. J Laryngol Otol 2005;119:391-95.
  10. Mattox DE, Reichert M. Meniett device for Meniere’s disease: use and compliance at 3 to 5 years. Otol Neurotol 2008;29:29-32.
  11. Densert B, Sass K. Control of symptoms in patients with Ménière’s disease using middle ear pressure applications: two years follow-up. Acta Otolaryngol 2001:121;-616-21.
  12. Shojaku H, Watanabe Y, Mineta H, Aoki M, Tsubota M, Watanabe K, Goto F, Shigeno K. Long-term effects of the Meniett device in Japanese patients with Meniere’s disease and delayed endolymphatic hydrops reported by the Middle Ear Pressure Treatment Research Group of Japan. Acta Otolaryngol. 2011;131(3):277-283.
  13. Dornhoffer JL, King D. The effect of the Meniett device in patients with Ménière’s disease: long-term results. Otol Neurotol 2008;29:868-74.
  14. Watanabe Y, Shojaku H, Junicho M, Asai M, Fujisaka M, Takakura H, Tsubota M, Yasumura S. Intermittent pressure therapy of intractable Meniere’s disease and delayed endolymphatic hydrops using the transtympanic membrane massage device: a preliminary report. Acta Otolaryngol. 2011;131(11):1178-1186.
  15. Nevoux J, Barbara M, Dornhoffer J, Gibson W, Kitahara T, Darrouzet V. International consensus (ICON) on treatment of Ménière’s disease. Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Feb;135(1S):S29-S32. Epub 2018 Jan 12.
  16. American Academy of Otolaryngology – Head and Neck Surgery. Position statement: micropressure therapy. Revised on 3/20/2016; http://www.entnet.org/Practice/micropressure.cfm . Accessed January 16, 2018.
  17. Ödkvist LM, Bergenius J, Möller C. When and how to use gentamicin in the treatment of Meniere’s disease. Acta Otolaryngol (Stockh) 1997; Suppl 526: 54–57.